Wei Wen Li

8184120, May 22, 2012

Feb 17, 2009

12/371959

Wei Hong - Edison NJ, US
Wei Li - Princeton NJ, US

Siemens Aktiengesellschaft - München

G06T 17/00
G06T 15/00
G06T 15/04

345424, 345582

Described herein is a system and method for facilitating large volume data processing and rendering. An exemplary system includes at least one processor coupled to a first memory, wherein the processor is configured to organize the large volume data in the first memory into one or more bricks. In addition, at least one graphics processing unit (GPU) is coupled to the processor and a second memory. The GPU is configured to process at least one or more bricks transferred from the first memory to the second memory to produce intermediate processing results, and to further render the intermediate processing results.

8563543, Oct 22, 2013

Oct 6, 2010

13/392955

Jack D. Scott - Scotch Plains NJ, US
Andrew W. Stamford - Chatham NJ, US
Eric J. Gilbert - Scotch Plains NJ, US
Jared N. Cumming - Garwood NJ, US
Ulrich Iserloh - Hoboken NJ, US
Lingyan Wang - East Brunswick NJ, US
Wei Li - Belle Mead NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

A61K 31/54

5142225, 544 8

In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (a) and include tautomers, solvates, prodrugs, esters, and deuterates thereof, and pharmaceutically acceptable salts of said compounds, tautomers, solvates, prodrugs, esters, and deuterates, wherein each of R, R, R, R, R, R, ring A, ring B, ring C, m, n, p, q, -L-, -L-, L-, and L- is selected independently and as defined herein. The compounds of the invention have, surprisingly and advantageously, improved solution stability. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers Disease, are also disclosed.

20030151604, Aug 14, 2003

Nov 21, 2002

10/301399

Arie Kaufman - Plainview NY, US
Wei Li - Stony Brook NY, US

RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK

G06T015/00

345/419000

A system and method for texture-based volume rendering accelerated by contouring texture hulls is provided. Bounding geometries, such as rectangles, cuboids, or the like surrounding the non-empty regions as well as the contouring borders of the non-empty regions are found. The bounding shapes are treated as the hulls of the non-empty sub-textures. The nonempty sub-textures are stored and rendered. Texels outside the hulls are skipped.

20090029906, Jan 29, 2009

May 1, 2006

11/913038

Rui Rong Yuan - Fort Lee NJ, US
Wei Ping Li - Kearny NJ, US
Joseph Menonna - Dumont NJ, US
Yasuhiro Maeda - Belle Mead NJ, US
Peter Dowling - Fort Lee NJ, US

UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY - Newark NJ

C07K 14/575
C07K 9/00
A61K 38/22
A61K 38/14
A61P 29/00
A61P 37/00

514 8, 530397, 530322

The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.

20220310072, Sep 29, 2022

Jun 3, 2020

17/616129

- Mountain View CA, US
Ruoming Pang - New York NY, US
David Rybach - Mountain View CA, US
Yanzhang He - Palo Alto CA, US
Rohit Prabhavalkar - Mountain View CA, US
Wei Li - Fremont CA, US
Mirkó Visontai - Mountain View CA, US
Qiao Liang - Redwood City CA, US
Trevor Strohman - Sunnyvale CA, US
Yonghui Wu - Fremont CA, US
Ian C. McGraw - Menlo Park CA, US
Chung-Cheng Chiu - Sunnyvale CA, US

G10L 15/16
G10L 15/32
G10L 15/05

Two-pass automatic speech recognition (ASR) models can be used to perform streaming on-device ASR to generate a text representation of an utterance captured in audio data. Various implementations include a first-pass portion of the ASR model used to generate streaming candidate recognition(s) of an utterance captured in audio data. For example, the first-pass portion can include a recurrent neural network transformer (RNN-T) decoder. Various implementations include a second-pass portion of the ASR model used to revise the streaming candidate recognition(s) of the utterance and generate a text representation of the utterance. For example, the second-pass portion can include a listen attend spell (LAS) decoder. Various implementations include a shared encoder shared between the RNN-T decoder and the LAS decoder.

20200306176, Oct 1, 2020

Mar 27, 2019

16/366404

- Edison NJ, US
Wei LI - Edison NJ, US
Zhihong ZHANG - Edison NJ, US

A61K 9/00
A61K 31/4422
A61K 47/10
A61K 47/38
A61K 47/32
A61K 31/55

Disclosed is an osmotic pump controlled release formulation, comprising a core and a membrane, wherein the membrane is coated on an outer surface of the core, the formulation has at least one channel, the core is communicated with to the outer surface of the formulation via the channel, lateral length of the channel is 1.40 mm-2.50 mm, and depth of the channel is 2.05 mm-2.95 mm.

20200206310, Jul 2, 2020

Jan 16, 2020

16/744326

- Manhasset NY, US
Wei Li - Plainview NY, US
Kevin J. Tracey - Old Greenwich CT, US
Ping Wang - Roslyn NY, US

A61K 38/17
A61K 39/395
C07K 14/00
C07K 16/18
A61P 31/02
A61K 31/704
A61K 31/22
A61K 31/19

Methods of treating sepsis or endotoxemia in a subject comprising administering to the subject an amount of an antagonist of a Panx1 hemichannel protein or an amount of an antagonist of a Cx43 hemichannel protein.

20200190159, Jun 18, 2020

Jun 4, 2018

16/617811

- Manhsset NY, US
Wei Li - Plainview NY, US
Jianhua Li - New York NY, US
Kevin J. Tracey - Old Greenwich CT, US

C07K 14/705
C07K 7/08
A61P 7/00
A61P 29/00

A method of treating a disease or reducing the development of a symptom of a disease in a subject by administering to the subject an amount of tetranectin protein or a tetranectin peptide agonist effective to treat or reduce development of the disease or disease symptom.